Bryan Schneider

Sep 9, 2024 | news.iu.edu | Bryan Schneider

Breast cancer remains the most common cancer diagnosis in women in the United States, and enduring the often debilitating cancer treatments can become as harrowing as the diagnosis itself. That’s especially true for Black women, who face disparate outcomes in breast cancer and are more likely to experience neuropathy.

Aug 17, 2024 | nature.com | Bryan Schneider

AbstractHuman induced pluripotent stem cell-derived sensory neuron (iPSC-dSN) models are a valuable resource for the study of neurotoxicity but are affected by poor replicability and reproducibility, often due to a lack of optimization. Here, we identify experimental factors related to culture conditions that substantially impact cellular drug response in vitro and determine optimal conditions for improved replicability and reproducibility.

Jun 3, 2024 | brnw.ch | Bryan Schneider |Sofía García |David Cella

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Jun 3, 2024 | medicine.iu.edu | Bryan Schneider |Kathy D. Miller

INDIANAPOLIS — Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with a chemotherapy called docetaxel experience less of a harmful side effect called peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.

Sep 7, 2023 | onclive.com | Bryan Schneider

Bryan Schneider, MD, clinical professor, service chief, Department of Internal Medicine, Division of Hematology/Oncology, associate medical director, Office of Research, service chief member, Rogel Cancer Center, University of Michigan Health, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer (NSCLC).